Effect of Synbiotic Supplementation on Maternal and Neonatal Outcomes in Pregnant Women With Pre-eclampsia: Study Protocol for a Triple Blind Randomized Controlled Clinical Trial

Rouhina Movaghar¹, Shamci Abbasalizadeh², Azizeh Farshbaf-Khalili³*, Mahnaz Shahnazi⁴*

Abstract

Objectives: Background: Pre-eclampsia is one of the main causes of premature birth, growth restriction, and intrauterine death of fetus. Probiotics has the potential to modulate inflammatory and oxidative stress biomarkers that implicated in the pathophysiology of pre-eclampsia. The aim of the present study is to establish the impact of synbiotic supplements, comprising of probiotic and prebiotic fructooligosaccharide, in comparison to placebo, on the maternal and neonatal outcome outcomes in women afflicted with mild pre-eclampsia.

Methods: This is a study protocol of a randomized, controlled, phase 3, triple-blind, randomized clinical trial. The classification is based on the gestational age at the time of diagnosis of mild pre-eclampsia (early-onset or late-onset pre-eclampsia). Participants will be 128 pregnant women with mild pre-eclampsia (systolic blood pressure between 140-160 mm Hg or diastolic blood pressure between 90-110 mm Hg, along with other pre-eclampsia symptoms). Participants will divided into two intervention and control groups using a 1:1 random allocation ratio randomly. They will receive one oral capsule (the concentration of 10⁹ CFU) or placebo daily from admission until delivery. Primary outcomes included mean systolic and diastolic blood pressure, mean gestational age from diagnosis to delivery, and mean birth weight. Also, secondary outcomes included proteinuria, serum creatinine level, the incidence of severe PE, the use of antihypertensive drugs, the rate of natural delivery, incidence of serious complications, maternal blood factors such as platelet count, and serum levels of liver enzymes such as ALT, AST, bilirubin, and LDH.

Discussion: The present trial can importantly contribute to the selection of an appropriate Synbiotic supplement as safe pharmaceutical adjuvants in the treatment of pregnant women with mild pre-eclampsia and prevention of maternal and neonatal complications.

Trial Registration: IRCT20110606006709N20. Registered on August 13, 2022.

Keywords: Pre-eclampsia, Gestational hypertension, Probiotic, Synbiotic, Pregnancy outcomes
The present trial can contribute to selecting an appropriate placebo on maternal, neonatal outcomes in mothers with mild preeclampsia and the prevention of its subsequent maternal and neonatal complications. It is suggested to consider a probiotic group in addition to the synbiotic and placebo groups in future studies.

**Key Messages**

- The aim of this study is to determine the effect of synbiotic supplements (probiotic with prebiotic) in comparison with indigestible carbohydrates (23).

**Materials and Methods**

This is a study protocol of a randomized, controlled, phase III, triple-blind, randomize clinical trial. Stratification shall be executed with respect to gestational age during the point of diagnosis of mild preeclampsia, distinguished as early-onset or late-onset preeclampsia. Envelopes numbered 1 to 100 will be allocated to late-onset preeclampsia, and envelopes 100 to 128 will be allocated to early-onset preeclampsia. Participants, researchers, outcome valuators, and statistical analysts will not be aware of the type of intervention received. The research population will be pregnant women referring to the high risk pregnancy clinic of Tabriz University of Medical Sciences. The research samples comprise 128 expectant mothers in their second trimester who have been diagnosed with mild preeclampsia and will be directed to the high-risk pregnancy clinic at this medical facility.

**Inclusion Criteria**

1) The diagnosis of mild preeclampsia is established when systolic blood pressure reaches or exceeds 140 mm Hg or diastolic blood pressure reaches or exceeds 90 mm Hg for the first time after the 20th week of pregnancy, which is accompanied by proteinuria or multi-organ involvement, such as renal, liver, nervous system dysfunction or pulmonary edema (13).

2) Single pregnancy with a live fetus

3) Gestational age over 24 weeks

4) Maternal age less than 45 years

5) Maternal age less than 45 years

6) The suitability of maternal and fetal conditions for expectant management.

**Exclusion Criteria**

1) Women who have been diagnosed with cardiovascular diseases

2) Women with hepatic and renal failure

3) Severe and chronic high blood pressure

4) Gestational and chronic diabetes

5) A history of allergy to probiotics or synbiotics

6) Acute gastrointestinal problems

7) Acute or chronic diseases

8) Use of glucocorticoid and immunosuppressive drugs (unless corticosteroids are prescribed for fetal lung maturation).

9) Maternal or fetal conditions that require immediate delivery. Conditions unrelated to preeclampsia (such as premature rupture of the sac or true umbilical cord knot leading to severe fetal distress) and conditions related to preeclampsia (such as fetal intrauterine growth restriction, percentile growth of less than 10%, color
Doppler ultrasonography disorder, placenta abruption, pulmonary edema, and eclampsia).

10) Intake of probiotic or synbiotic supplements and foods such as probiotic yogurt in the last three months.

Intervention type

The intervention group will receive LactoCare synbiotic capsule manufactured by ZistTakhmir Company. The probiotic and prebiotic strains will be included:

- **Lactobacillus casei**: $3 \times 10^9$
- **Lactobacillus acidophilus**: $3 \times 10^9$
- **Lactobacillus rhamnosus**: $7 \times 10^9$
- **Lactobacillus bulgaricus**: $5 \times 10^9$
- **Bifidobacterium longum**: $1 \times 10^9$
- **Bifidobacterium breve**: $2 \times 10^{10}$
- **Streptococcus thermophiles**: $3 \times 10^9$
- **Fructose oligosaccharides**: 38.5 mg

The control group will receive the placebo inactive capsules, which will be similar in appearance and color to the symbiotic capsules made by the ZistTakhmir Company and include maltodextrin, lactose magnesium stearate. Both groups will take the capsules from the time of enrollment until delivery. All trial participants will receive usual care usual care in addition to the study capsules. Both groups will be advised not to take probiotic products during the intervention other than the capsules received in this study and reduce salt intake and physical activity.

Sample Size

The calculation of the sample size was based on the consideration all four variables of birth weight, blood pressure (systolic and diastolic), and duration of pregnancy from diagnosis to delivery by G*Power software (version 3.1.2) using the difference between two independent means formula. Based on the study by Chappell et al (24) for birth weight variable (gram), taking into account mean 1 = 2670, mean 2 = 2803, standard deviation (sd) 1 = sd 2 = 234.25, power 80%, $\alpha = 0.05$ and two-tailed test, 55 individuals was calculated for each group considering 10% drop out.

Concerning diastolic blood pressure variables (mm Hg): mean 1 = 107, mean 2 = 96, sd 1 = sd 2 = 12 power 80%, $\alpha = 0.05$ and two-tailed test, 39 individuals was calculated for each group considering a 10% drop out.

According to the study by Chappell et al (24) on the variable of gestational age at delivery (day) and taking into account mean 1 = 262/5 and mean 2 = 267.5, sd 1 = sd 2 = 7.35, power 80%, $\alpha = 0.05$ and two-tailed tests, the sample size was calculated 39 people for each group considering the 10% drop out.

According to the study by Cluver et al (25) on the duration of pregnancy from diagnosis to delivery (day) and taking into account power 80%, with mean 1 = 8.3, mean 2 = 10.3 and sd 1 = sd 2 = 3.95, $\alpha = 0.05$, the sample size calculated 64 individuals for each group (the obtained maximum sample size), considering 3 10% sample drop.

Data Collection Tools

1. Eligibility criteria checklist: It includes the inclusion and exclusion criteria that individuals will complete at the beginning of the study to enter the study if they qualify.

2. Demographic and obstetric questionnaire: It includes demographic and pregnancy-delivery information (questionnaire code, age, education, spouse's education, occupation, income, smoking, alcohol, and drug use, number of pregnancies, abortion, last menstrual period (LMP), weight, height, etc.) that people will complete after entering the study.

3. Daily medication checklist and medication side effects: This checklist, along with training on how to use the medication or placebo, will be marked by the participants whenever the daily capsule is used in the relevant table indicating the days of the week. At the end of the questionnaire, a list of side effects has been listed which will be marked in case of complications.

4. Mothers' food recall form: This diary will be delivered to the participants at the beginning of the study to record the food consumed within three days before admission.

5. Pregnancy, delivery, and neonatal outcomes questionnaire: It includes the information on pregnancy and childbirth (gestational age at delivery based on early ultrasound, in its absence by the LMP, pretreatment test results, type of delivery, premature rupture of membranes, any serious complications such as at least one cases: Stroke, kidney failure, liver failure, HELLP syndrome, intravascular coagulation, pulmonary edema, severe preeclampsia, antihypertensive drug use), and neonatal characteristics (Apgar score less than seven min, weight, Height, fetal head circumference, fetal death, neonatal death, preterm birth, neonatal intensive care unit over seven days, LBW, the use of surfactants, intubated and mechanical ventilation).

6. Laboratory tests record sheet: Urine protein, serum creatinine, complete blood count (CBC), platelet, liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]), bilirubin, lactate dehydrogenase (LDH) will be recorded in this sheet.

7. Blood pressure record sheet: Blood pressure will be measured in a sitting position at hospital admission, once every 4 hours using the ISOMED mercury barometer with $\pm 3$ mm Hg error, from the right hand. So that the arm should be placed at the heart level it will be recorded separately for systolic and diastolic blood pressure.

8. Checklist of side effects of the drug: Content validity will be used in this study to obtain the scientific validity of the tools.

Procedure

The researcher will prepare the questionnaires according
to the purpose of the study by studying the authoritative books and journals. Ten members of the faculty of Tabriz University of Medical Sciences will be given questionnaires to review, provide comments on, and finally confirm.

The questionnaires will then be used for research after approval of their validity and reliability.

Initially, the sampling will be done in an easy or accessible manner, so that the researcher will refer to the high-risk pregnancy clinics of Al-Zahra hospital affiliated to Tabriz University of Medical Sciences. After introducing himself and outlining the purpose of the study and briefly explaining the process of conducting the research and eligibility criteria, the researcher will proceed with the initial enrollment of those interested in participating in the study. The study population will be pregnant women diagnosed with mild preeclampsia. First, all participants will be visited by a perinatologist and then the researcher will review the inclusion criteria and complete the relevant checklist for each patient.

The individuals who take part in the study shall be split into two distinct categories - synbiotic and placebo - via randomized blocks, with an allocation ratio of 1:1. The allocation sequence will be determined by a researcher not involved in this study using RAS (Random Allocation Software).

Equal to the number of samples, envelopes will be provided. Each envelope will be numbered from 1 to 128. The envelopes will be standardized, sealed, opaque, and consist of 14 capsules. The preparation of them will be carried out by an uninvolved individual in the research (Figure 1).

The Stratification will be based on gestational age during mild preeclampsia diagnosis (early or late preeclampsia). In this study, the main and placebo supplements will be similar in shape, color, odor, and dose, and the researcher, patients, and data analyzer will be blinded. The enrollment, interventions, and evaluations schedule is presented in Figure 2.

If the 6-month period is not sufficient for sampling, the length of the sampling period will be increased. Also we will refer to Taleghani hospital in Tabriz affiliated to Tabriz University of Medical Sciences. The researcher will introduce the study objectives to all eligible women and, after obtaining written and signed informed consent from the patients, will complete the basic information form. The initial envelope will be distributed to the first qualified individual and the procedure will proceed until the sample is finished. The patients will be taught how to use the medication correctly so that from the time of enrollment until the end of pregnancy take one capsule with a glass of water every day after meals before bedtime. So that, every day after meals, before going to bed, take a capsule with a glass of water.

During the intervention period, the correct use and daily side effects will be monitored by the research team (perinatologist, head of the high-risk pregnancy department who will visit the participants daily, researcher and colleague of the high-risk pregnancy ward) who will be blinded. Individuals will receive a table with the days of the week and must mark it daily after taking capsules. After each envelope, they should return the empty one to the researcher. They will then receive the next envelope. In both groups, synbiotic and placebo capsules will be used in addition to usual care and treatment according to the
Figure 2. Time schedule of Enrolment, Interventions, and Assessments.

<table>
<thead>
<tr>
<th>Timepoint</th>
<th>Study Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Enrolment</td>
</tr>
<tr>
<td></td>
<td>Refer to the clinic</td>
</tr>
<tr>
<td><strong>Enrolment:</strong></td>
<td></td>
</tr>
<tr>
<td>Eligibility screen</td>
<td>X</td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
</tr>
<tr>
<td>Stratification</td>
<td></td>
</tr>
<tr>
<td>Allocation</td>
<td></td>
</tr>
<tr>
<td><strong>Interventions:</strong></td>
<td></td>
</tr>
<tr>
<td>Synbiotic</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>X</td>
</tr>
<tr>
<td><strong>Assessments:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>[List baseline variables]</strong></td>
<td></td>
</tr>
<tr>
<td>Blood pressure, proteinuria, gestational age, weight, height, BMI</td>
<td>X</td>
</tr>
<tr>
<td><strong>[List outcome variables]</strong></td>
<td></td>
</tr>
<tr>
<td>Mean systolic blood pressure</td>
<td>X</td>
</tr>
<tr>
<td>Mean diastolic blood pressure</td>
<td>X</td>
</tr>
<tr>
<td>Mean duration of pregnancy from diagnosis to delivery</td>
<td></td>
</tr>
<tr>
<td>Mean birth weight</td>
<td>X</td>
</tr>
<tr>
<td><strong>[List other data variables]</strong></td>
<td></td>
</tr>
<tr>
<td>Incidence of severe preeclampsia</td>
<td>X</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>X</td>
</tr>
<tr>
<td>Anti-hypertensive drug use</td>
<td>X</td>
</tr>
<tr>
<td>Elective delivery rate</td>
<td>X</td>
</tr>
<tr>
<td>Normal delivery rate</td>
<td>X</td>
</tr>
<tr>
<td>Severity of serious complications</td>
<td>X</td>
</tr>
<tr>
<td>Average fetal age at termination of pregnancy</td>
<td></td>
</tr>
<tr>
<td>Neonatal death</td>
<td>X</td>
</tr>
<tr>
<td>Fetal death</td>
<td>X</td>
</tr>
<tr>
<td>Preterm birth</td>
<td>X</td>
</tr>
<tr>
<td>Infant special care of more than 7 days</td>
<td>X</td>
</tr>
<tr>
<td>Low birth weight</td>
<td>X</td>
</tr>
<tr>
<td>Average of weight</td>
<td>X</td>
</tr>
<tr>
<td>Average of height</td>
<td>X</td>
</tr>
<tr>
<td>Average of head circumference</td>
<td>X</td>
</tr>
<tr>
<td>Apgar score less than 7 in 5th min</td>
<td></td>
</tr>
<tr>
<td>Surfactant use</td>
<td>X</td>
</tr>
<tr>
<td>Intubation and mechanical ventilation</td>
<td></td>
</tr>
<tr>
<td>Continuous positive airway pressure</td>
<td></td>
</tr>
<tr>
<td>Possible side effects of synbiotic capsules and placebo</td>
<td>X</td>
</tr>
</tbody>
</table>

national protocol. Patients will be given a contact number for inquiries or issues. In case of emerging complications that may be related to our intervention, the intervention will be stopped, but monitoring will be continued due to the intention to treat (ITT) approach and the study outcomes will be evaluated. People who receive less than 7 days due to childbirth or unwillingness to take complementary medicine will be reported. From the researcher who will generate the allocation sequence will be inquired about the type, and complications will be noted. At the end of the study, the quantity of ingested medicines and marked sheets will be checked for calculating the compliance rate of capsules. Paper forms will be used to collect data and the research team will be involved in gathering information. In order to maintain the confidentiality of participants' information, questionnaires with anonymous numbers will be used. Data monitoring committee will monitor this study and if necessary, interim analysis will be performed.
The Study Outcomes

The primary outcomes of the study are mean systolic and diastolic blood pressure, duration of pregnancy from diagnosis to delivery, birth weight and, gestational age (Table 1). For achieving these outcomes, the average of all measurements of systolic and diastolic blood pressure every day from diagnosis until delivery will be compared between groups. The other aim to investigate how our intervention impacts the length of pregnancy and average fetal age at delivery. To account for the confounding effect of gestational age, we will stratify based on when mild preeclampsia was diagnosed (early or late, i.e. before or after 34 weeks gestation). Then, in the analysis of outcome (comparison of duration of pregnancy from diagnosis to delivery, and fetal age at delivery between groups), at the time of diagnosis we will adjust the gestational age. At birth, a lever scale (Seca, Germany) will be used to measure birth weight with minimal coverage.

The secondary outcomes related to maternity include proteinuria, incidence of severe pre eclampsia, antihypertensive drug usage, elective delivery rate (labor induction or cesarean section), vaginal delivery rate, severity of serious complications (HELLP syndrome, stroke, kidney failure, liver failure, intravascular coagulation, pulmonary edema), maternal blood factors, and serum levels of liver enzymes such as ALT, AST, bilirubin, and LDH. The neonatal secondary outcomes are neonatal death, fetal death, preterm birth, infant intensive care of more than seven days, LBW, the average weight, height, and head circumference, Apgar score less than seven in 5th min, surfactant use, intubation, and mechanical ventilation, continuous positive airway pressure, possible side effects of synbiotic capsules and

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Primary Outcomes</th>
<th>Secondary Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mother objectives</strong></td>
<td>Mean systolic blood pressure</td>
<td>Proteinuria</td>
</tr>
<tr>
<td></td>
<td>Mean diastolic blood pressure</td>
<td>Incidence of severe pre eclampsia</td>
</tr>
<tr>
<td></td>
<td>Mean duration of pregnancy from diagnosis to delivery</td>
<td>Antihypertensive drug use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elective delivery rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vaginal delivery rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severity of serious complications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Side effects of synbiotic capsules</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serum creatinine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Platelet count</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AST</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilirubin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDH</td>
</tr>
<tr>
<td></td>
<td>Mean birth weight</td>
<td>Neonatal death</td>
</tr>
<tr>
<td></td>
<td>Gestational age</td>
<td>Fetal death</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preterm birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infant intensive care of more than 7 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LBW</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Average weight</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Average height</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Average head circumference</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Apgar score less than seven in 5th min</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surfactant use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intubation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mechanical ventilation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Continuous positive airway pressure</td>
</tr>
</tbody>
</table>

Table 1. Primary and Secondary Outcomes of the Study
placebo (Table 1). These outcomes will be complemented by study measurement tools (described in the previous section) based on clinical and laboratory examinations and information in the patient's medical records. The height of the newborn will be measured without shoes or hats using a stadiometer table while they are in the supine position. The neonatal head circumference will be measured using a tape measure from the occipital prominence to the forehead, without any headwear. Birth weight below 2500 g is considered as LBW. Labor occurring between 20 to 37 weeks of pregnancy will be considered as preterm labor.

Data Management
To manage the data, unique codes will be given to individuals from 1 to 128 and will be recorded in their questionnaires. The participants data will enter into the SPSS software with the same code. Information will be collected from valid questionnaires and will be entered into SPSS software by two people separately to guarantee the precision and quality of the data. The entry made by the second individual, also known as the second pass entry, plays a pivotal role in verifying and reconciling data by detecting transcription errors and discrepancies arising from illegible data (26). The data of people relating to protocol non-adherence, will be included in the analysis.

According to national protocol for mild preeclampsia, in case of clinical diagnosis, the management routinely includes hospital admission and maternal and fetal close supervision, and decisions are made based on gestational age. In the event of severe preeclampsia, termination of pregnancy will be performed and included in the analysis.

Primary care includes evaluation of signs and symptoms (headache, visual disorder, epigastric pain, and sudden weight gain of about 1.5 kg/wk), measurement of uterine height and gestational age, daily weighing, relative rest, protein-rich diet, high-calorie food, sitting blood pressure monitor every 4 hours (except midnight to 6 am if blood pressure is controlled), using the ISOMED mercury barometer. It will be measured with a ±3 mm Hg error.

Urinary protein measurement at admission and if the proteinuria is +1 or higher or the protein/creatinine ratio is 0.3 or higher, 24-hour urine collection will be performed.

In the case of 24-hour urine proteinuria, no further tests will be required to repeat the test, and serum creatinine levels will be sufficient to evaluate renal function. CBC measurements, especially platelets, creatinine, liver enzymes, bilirubin, LDH testing will be repeated two to three times weekly, depending on maternal conditions and severity of blood pressure.

Fetal health assessments include daily heart rate hearing, fetal movement control, an initial ultrasound to monitor fetal growth and then every three weeks, fetal health control with biophysical profiles (amniotic fluid index and non-stress test): The interval between tests will depend on the gestational age, the severity of the disease and intrauterine growth disorder, amniotic fluid index and fetal Doppler changes.

If the duration of pregnancy is under 37 weeks, symptoms should be reviewed regularly and primary care will be provided until delivery.

Pregnancy can be terminated if the gestational age is 37 weeks or more. Magnesium sulfate will be injected in the active phase of the patient's delivery.

In this study, an academic staff as a representative of the ethics committee will monitor research day-to-day and will report the process of intervention to the ethics committee in three stages: The beginning of the intervention, during the intervention, data analysis, and final reporting. She/he is independent of sponsors and competing interests.

Statistical Analysis
The results will be entered into SPSS 24 and the normality of the quantitative data will be analyzed through the Kolmogorov-Smirnov test. The study will utilize the general linear model adjusted for baseline and potential confounders to compare mean quantitative variables among groups.

A binary logistic regression model will be utilized for comparison of binary variables between study groups, with adjustment for potential confounding variables. All calculations will be based on ITT and α=0.05 with a 95% confidence interval at all stages. Random assignment of individuals to groups will greatly control the confounding variables. If there be significant disparities between the study groups in the baseline characteristics (demographic and obstetric variables), they will be statistically adjusted.

The important baseline characteristics such as the baseline value of outcomes (baseline blood pressure and proteinuria), age, and body mass index, vitamin D3 intake, … (according to the clinical justification) will be adjusted. For managing missing data, we considered 10% of the sample drop for each group. If the drops are more than 10%, the expectation-maximization will be used for the estimation of missing values.

Discussion
Preeclampsia is a condition that endangers the life of both the mother and fetus, with severe maternal and perinatal complications. If the treatment is found, it could have a major impact on reducing the complications of this disorder and increasing the health of mothers and babies. Currently, no effective treatment exists except for delivery of the fetus and placenta (27). The suggested therapies that have reached human trials are very few. In many countries, preventive interventions can be quite valuable, even with small or medium benefits.

Preeclampsia is linked to oxidative stress and inflammation. A potential treatment for preeclampsia may involve a drug that reduces soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng), as well
as endothelial dysfunction and oxidative stress. In this study, considering the etiology of preeclampsia and the mechanism of the effect of probiotic and synbiotic supplementation, it is suggested that these supplements can be prescribed as a possible treatment for preeclampsia. There are no anticipated problems about probiotics that are detrimental to the participant (22).

We plan to enroll 128 women with preeclampsia at Al-Zahra hospital, located in downtown Tabriz. The reason for choosing this hospital for sampling is that this hospital is a third-level referral center that has a neonatal and maternal special care unit. It is an academic center, with most pregnant mothers suspected of having preeclampsia belonging to various socio-economic levels in the province referred to this center. The results might potentially be generalizable to developed and developing countries.

Previous studies of esomeprazole for early-onset preeclampsia have suggested that it is a class-C drug during pregnancy is classified by the Food and Drug Administration (FDA). Group-C pertains to pharmaceuticals that have been observed to have unfavorable impact on animal fetal reproduction, lacking sufficient and appropriately controlled studies in humans (27).

Pravastatin has also been suggested for early preeclampsia and at-risk women. However, the drug is assigned to Group-X in pregnancy by the FDA classification system and database for the administration of pregnancy drugs. FDA-class-X drugs are medications which have been tested in animals or humans and have demonstrated a risk of fetal abnormalities and/or harm to humans during pregnancy (28).

Probiotics have great potential as therapeutic approaches in pregnancy and have many beneficial effects in controlling atopic disorders (29). Observational studies indicate a correlation between consuming milk with probiotics and a decreased likelihood of preeclampsia and preterm labor (21).

These dietary supplements can reduce systemic inflammation and oxidative stress (19), and promote digestive health by suppressing pathogenic bacteria. They also modify physiological processes related to hypertension, inflammation, kidney function, and diabetes (20). The most important probiotic success factors in the treatment of inflammation, oxidative stress, and metabolism depend on the type and origin of the process. The probiotic Lactobacillus and Bifidobacterium species have been extensively researched and used. Lactobacillus is especially known as anti-inflammatory, anti-oxidative, anti-coagulant, anticancer, and anti-diabetic (30, 31). Previous studies have demonstrated the anti-inflammatory, anti-oxidant, anti-lipidemic, and immune-enhancing properties of Bifidobacterium species (32).

Probiotic strains are able to limit a large amount of free reactive radicals in the body and help prevent and control several oxidative stress-related diseases. In general, these supplements affect inflammatory biomarkers and oxidative stress (19).

The mechanism of the probiotic's anti-inflammatory response is through the modulation of the expression of genes related to gut inflammation and blood pressure, such as the mechanism of anti-inflammatory drugs (29). They also decrease the expression of lipopolysaccharide of gram-negative bacteria, thereby reducing their inflammation, especially the inflammation in human placental trophoblast cells (33).

Another mechanism of the effect of probiotics is their antioxidant activity by inhibiting the oxidation process (34). Probiotics have the ability to generate certain B-group vitamins, which possess antioxidant characteristics (35) and are instrumental in the removal of superoxide and hydroxyl radicals (36). It has also been suggested that probiotic bacteria generate short-chain fatty acid, which blocks the synthesis of serum high-sensitivity C-reactive protein by blocking hepatic enzymatic synthesis (37). Probiotics also regulate the production of fatty acids (38), thereby, the occurrence of inflammatory enzymes is hindered and the antioxidant status is enhanced (39). Some biological peptides produced by probiotics have disinfectant activities and kill free radicals (40).

A systematic review, entitled "Probiotics in Pregnancy and Maternal Results" was conducted in 2013, including randomized controlled trials and prospective cohort studies. This study demonstrated that the utilization of probiotics exhibits a safeguarding impact on the prevalence of preeclampsia. In a cohort study, probiotic-containing dairy products were linked to a lower risk of preeclampsia, especially severe preeclampsia. The results of this review study also reported significant positive effects of the probiotic on lowering maternal blood glucose and decreasing insulin intake as well as incidence of gestational diabetes (29).

A triple-blind controlled clinical trial was conducted to evaluate the effect of probiotic supplementation on blood pressure in pregnant women with gestational diabetes mellitus. The aim of this study was to determine the effect of probiotic supplementation on factors such as systolic blood pressure (SBP) and diastolic blood pressure (DBP). The intervention group did not have increased blood pressure compared to baseline. However, the control group had significantly higher SBP and DBP than at baseline (41). It has been shown that probiotic and synbiotic supplements can significantly reduce hepatic statuses, ALT, AST and improve conditions of liver (42,43), serum creatinine (44), proteinuria (45), bilirubin (46).

Prebiotics promote the growth or activity of beneficial bacterial species (probiotics) in the gut and, on the other hand, inhibit the establishment and proliferation of certain pathogenic bacteria such as Salmonella. Moreover, as a source of fermentable substrates that support the proliferation of probiotic microorganisms, particularly lactobacilli and bifidobacteria, dietary
fiber supplementation has numerous advantageous physiological impacts. Additionally, probiotic encapsulation agents are utilized to enhance the stability of these microorganisms in food formulations (23). As for the safety of probiotic and prebiotic supplements, these supplements are unlikely to enter the body’s circulatory system and damage the immune system (47). Studies in pregnancy have so far shown no adverse effects on the mother and fetus other than their positive effects. Because these supplements are used for the treatment after the first trimester, they are unlikely to affect angiogenesis. Their systemic absorption is very rare and no risk has been reported (22).

Considering that this disease is considered as a global-health problem and is related with a very high rate of morbidity and mortality of mothers and neonatal, in many countries, preventive and therapeutic interventions, even with small or moderate benefits, can be considered very valuable.

Study Limitations

1) In premature infants, the Apgar score is not a very good criterion for diagnosing neonatal asphyxia (27).
2) There are several gynecologists and pregnancy termination decisions. But given that the training centers run the patients according to the protocol of the Ministry of Health and treatment, this limitation will be somewhat manageable.
3) We will compare a synbiotic supplementation with the placebo. No probiotic group is considered.

Authors’ Contribution

Conceptualization: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi, Shamci Abbasalizadeh.
Methodology: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi, Shamci Abbasalizadeh.
Validation: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi, Shamci Abbasalizadeh.
Formal analysis: Rouhina Movaghar, Azizeh Farshbaf-Khalili.
Investigation: Rouhina Movaghar.
Resources: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi.
Data curation: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi.
Supervision: Azizeh Farshbaf-Khalili, Mahnaz Shahnazi.
Project administration: Rouhina Movaghar, Mahnaz Shahnazi.
Funding acquisition: Mahnaz Shahnazi.
Writing-original draft: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi.
Writing-review and editing: Rouhina Movaghar, Azizeh Farshbaf-Khalili, Mahnaz Shahnazi, Shamci Abbasalizadeh.

Conflict of Interests

The authors declare that they have no competing interests.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Disclaimer

The funder will provide proper arrangements in place to initiate the study and will monitor study progress, but will not have a role in the conduct of the study and not contribute to the preparation of this manuscript. The study protocol has undergone peer review of the funding institute.

Ethical Issues

Written informed consents will be obtained from participants. The Ethics Committee of Tabriz University of Medical Sciences has approved the protocol (code of approved ethics: IR.TBZMED.REC.1398.556). Besides, this protocol has been registered at Iranian Registry of Clinical Trials (identifier: IRCT20110606001709N29; https://www.irct.ir/trial/39930).

Financial Support

This study will be financed by Tabriz University of Medical Sciences (Grant number: 63416).

References


